233764-32-4

Usage

Uses

Used in Pharmaceutical Industry:
Cyclohexanol, 4-amino-1-methyl(9CI) is utilized as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the creation of a wide range of medicinal compounds, contributing to the development of new treatments and therapies.
Used in Chemical Industry:
In the chemical industry, Cyclohexanol, 4-amino-1-methyl(9CI) is employed as a precursor for the production of diverse organic compounds. Its reactivity and functional groups make it a valuable component in the synthesis of specialty chemicals, polymers, and other materials.
Used in Agrochemical Production:
Cyclohexanol, 4-amino-1-methyl(9CI) has been studied for its potential use as an intermediate in the manufacturing of agrochemicals. Its incorporation into these products can enhance the effectiveness of pesticides, herbicides, and other agricultural chemicals, thereby improving crop protection and yield.
Used in Research and Development:
Cyclohexanol, 4-amino-1-methyl(9CI)'s unique properties also make it a valuable tool in research and development settings. Scientists and chemists use Cyclohexanol, 4-amino-1-methyl(9CI) to explore new chemical reactions, investigate its reactivity with other compounds, and develop innovative applications in various fields.

Upstream product

• 179321-49-4 N-(tert-butoxycarbonyl)-4-aminocyclohexanone 
• 233764-31-3 tert-butyl N-(4-hydroxy-4-methylcyclohexyl)carbamate 
• 17429-02-6 4-hydroxy-4-methylcyclohexanone 
• 952745-69-6 4-(benzylamino)-1-methylcyclohexanol 
• 66336-42-3 8-methyl-1,4-dioxa-spiro[4.5]decan-8-ol 
• 4746-97-8 cyclohexanedione monoethylene ketal 

Downstream Products

• 1610021-15-2 6-chloro-4-(cyclopropylamino)-N-(4-hydroxy-4-methylcyclohexyl)nicotinamide 

Relevant academic research and scientific papers

Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.

KETONE DERIVATIVES OF IMIDAZOLES, PHARMACEUTICAL COMBINATIONS AND USES THEREOF

This application relates to ketone compounds of imidazoles, pharmaceutically acceptable salts, solvents, polymorphs or prodrugs thereof, and further relates to pharmaceutical combinations comprising the foregoing substances and uses for preventing and treating protein kinase related diseases such as cancer, metabolic diseases, and cardiovascular diseases.

Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.

NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION

The invention provides novel compounds having the general formula: formula (I) wherein R1, R2, R3, R4, R5, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.

CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE

A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R1, R2, and R3 each independently represent a hydrogen atom, a fluoro group, or a C1 to C6 alkyl group; R4 represents a hydrogen atom or a prodrug group; and Y represents -CH2-CHR5-CH2-NHR6 (wherein R5 represents a hydrogen atom, a C1 to C6 alkyl group, or a C1 to C6 alkoxy group, and R6 represents a hydrogen atom or a prodrug group), or the like exhibits excellent TAFIa inhibitory activity and is useful as a therapeutic drug for myocardial infarction, angina pectoris, acute coronary syndrome, cerebral infarction, deep vein thrombosis, pulmonary embolism, and the like.

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

PICOLINAMIDE AND PYRIMIDINE-4-CARBOXAMIDE COMPOUNDS, PROCESS FOR PREPARING AND PHAMACEUTICAL COMPOSITION COMPRISING THE SAME

Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11β-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11β-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human- derived 11β-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LAD A), insulin tolerance syndromes, obesity, impaired glucose tolerane (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.

SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS

Compounds of Formula (I) and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.